DUBLIN, Ireland — Mallinckrodt plc has hired three new executives for its senior management team.
The pharmaceutical company said Thursday that it has appointed Hugh O’Neill as senior vice president and president of specialty pharmaceuticals; Gary Phillips as senior vice president and chief strategy officer; and Mario Saltarelli as senior vice president and chief science officer.
Together, the three executives bring to Mallinckrodt more than 70 years of experience in the pharmaceuticals sector.
O’Neill most recently held commercial leadership positions at Sanofi, including vice president, commercial excellence; general manager; president of Sanofi Canada; and vice president of market access and business development. He also has held leadership posts at Sandoz Pharmaceuticals, Forest Laboratories, Novartis and Pfizer.
Phillips comes to Mallinckrodt from the World Economic Forum in Geneva, Switzerland, where he was head of global health and health care industries. Before that, he served as president of Reckitt Benckiser Pharmaceuticals North America and president of U.S. pharmaceuticals and surgical at Bausch + Lomb. He has also been in positions of leadership at Merck Serono, Novartis, Wyeth-Ayerst and Gensia Pharmaceuticals.
At Mallinckrodt, Saltarelli will lead the recently consolidated functions of research and development, medical affairs and regulatory affairs. He joins the company from Shire plc, where he served as senior vice president of R&D. He previous held positions in R&D at Abbott Laboratories and Pfizer.
"I’m delighted to welcome Hugh, Gary and Mario to Mallinckrodt and to our senior management team," stated Mark Trudeau, president and chief executive officer of Mallinckrodt Pharmaceuticals. "Their combined years of experience and great strengths in their respective fields will help solidify our position as a science-based company, allow us to expand our core specialty pharmaceutical business, and position us to be more competitive in the marketplace. I am confident that, with these important additions to our senior leadership team, we are well-positioned to unlock our potential to become a competitive leader in the specialty pharmaceutical space."
